Ebola Treatment Shown to Work on Infected Monkeys

Global Security Newswire Staff
Add to Briefcase
See more stories about...
Global Security Newswire Staff
Aug. 22, 2013, 9:02 a.m.

A new Ebola drug grown from spe­cial to­bacco plants has been shown to cure mon­keys that were already dis­play­ing signs of in­fec­tion by the vir­al hem­or­rhagic fever, the Los Angeles Times re­por­ted on Wed­nes­day.

Oth­er Ebola coun­ter­meas­ures have been shown to work on in­fec­ted an­im­als be­fore they start dis­play­ing symp­toms of the highly vir­u­lent and leth­al dis­ease. However, this is the first time a drug has demon­strated any ef­fect­ive­ness after signs of the vir­us have mani­fes­ted. That is re­garded as a cru­cial cap­ab­il­ity in the event of a real-life dis­ease epi­dem­ic, ac­cord­ing to vir­o­lo­gist Gene Olinger, who works at the Army Med­ic­al Re­search In­sti­tute of In­fec­tious Dis­eases at Fort De­t­rick, Md.

“We’ve pushed the op­por­tun­ity to treat people to the point where they walk in and say, ‘I have a fever,’” said Olinger, co-au­thor of a re­port on the new Ebola drug pub­lished by the Sci­ence Trans­la­tion­al Medi­cine journ­al on Wed­nes­day. “A lot of folks in the field would have thought pro­tect­ing an an­im­al at the time of fever and viremia is too late to have a clin­ic­al be­ne­fit.”

Ebola is one of the most deadly and con­ta­gious dis­eases known to ex­ist in nature. The lack of ad­equate vac­cines and an­ti­dotes for the dis­ease have made it a ser­i­ous worry for biode­fense spe­cial­ists con­cerned about its pos­sible ap­plic­a­tions as a bio­lo­gic­al weapon.

In the re­cent study, sev­en in­fec­ted rhesus mon­keys were ad­min­istered the ex­per­i­ment­al treat­ment MB-003 through their veins once every three days. Three of the mon­keys did not die, res­ult­ing in a stat­ist­ic­ally not­able suc­cess rate of 43 per­cent.

Fort De­t­rick sci­ent­ist and lead study au­thor James Pet­titt said it is prob­able that in a real-life out­break, the drug would be ad­min­istered at a high­er dosage and with great­er fre­quency.

“We think we’ll get bet­ter res­ults,” the re­search­er said.

Grow­ing the drug from spe­cially de­veloped to­bacco leaves is not only less costly than con­ven­tion­al cell-based meth­ods, but also al­lows for large batches of the drug to be pro­duced on fairly short, weeklong sched­ules, ac­cord­ing to the Times art­icle.

Olinger said fur­ther meas­ures will be taken to im­prove MB-003 by adding to it more Ebola an­ti­bod­ies that were dis­covered by a dif­fer­ent group of re­search­ers.

What We're Following See More »
MEETING WITH SENATE GOP
Trump to Hill Next Tuesday
50 minutes ago
THE DETAILS
INTERPARTY FEUDING CONTINUES UNDER PEREZ
Longtime Progressive Members Pushed Out at DNC
1 hours ago
THE LATEST

"A shake-up is underway at the Democratic National Committee as several key longtime officials have lost their posts, exposing a still-raw rift in the party and igniting anger among those in its progressive wing who see retaliation for their opposition to DNC Chairman Tom Perez. The ousters come ahead of the DNC's first meeting, in Las Vegas, Nevada, since Perez took over as chairman with a pledge this year to unite a party that had become badly divided during the brutal Bernie Sanders-Hillary Clinton 2016 primary race."

Source:
LAST-DITCH FOR A FEW, SPECIFIC CASES
FDA Approves Personalized Cancer Therapy
3 hours ago
THE DETAILS
WILL RESIGN BY JAN. 31
Rep. Tiberi Confirms Resignation Report
4 hours ago
THE DETAILS

In a statement, Rep. Pat Tiberi (R-OH 12) confirmed a New York Times report that he would resign to lead the Ohio Business Roundtable. "While I have not yet determined a final resignation date, I will be leaving Congress by January 31, 2018."

Source:
AID DROPPED TO 222,000
Unemployment Claims Fall to Lowest in 44 Years
4 hours ago
THE DETAILS

"The number of Americans collecting unemployment benefits fell last week to the lowest level" since March 1973. According to the Labor Department Thursday, "claims for jobless aid dropped by 22,000 to 222,000." Additionally, "the less volatile four-week average slid by 9,500 to 248,250, lowest since late August."

Source:
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login